<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95698">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814956</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0813</org_study_id>
    <secondary_id>2011-003397-82</secondary_id>
    <nct_id>NCT01814956</nct_id>
  </id_info>
  <brief_title>Different Lipid Emulsions in Acute Lung Injury Patients</brief_title>
  <official_title>Prospective, Randomized, Controlled, Double-blind, Parallel-group, Mono-center, Explorative Phase IV Trial on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion Versus a Standard Soybean-oil Based Lipid Emulsion in Patients With Acute Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim is to investigate the influence of an early supply of parenteral nutrition including a
      fish oil containing lipid emulsion on the course of acute lung injury in the intensive care
      unit. In comparison, a standard parenteral nutrition with a soybean oil based emulsion will
      be used. Data obtained in this trial may provide evidence for a beneficial effect of fish
      oil derived omega-3 fatty acids in parenteral nutrition regarding their influence on acute
      lung injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in blood oxygenation (PaO2/FiO2ratio)</measure>
    <time_frame>change day 1 to day 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>day 1 to day 16</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment</measure>
    <time_frame>day 1 to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. lipid emulsion for parenteral nutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>i.v. lipid emulsion for parenteral nutrition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipoplus 20%</intervention_name>
    <description>Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipofundin N 20%</intervention_name>
    <description>Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Acute Lung Injury as a result of proven pneumonia (x-ray) or witnessed aspiration

          -  Oxygenation factor ≤ 300

          -  &lt;= 72 hours since intubation or non-invasive ventilatory support by mask at screening

          -  Expected need for parenteral nutrition for at least 5 days

          -  Male or female ≥ 18 years of age

        Exclusion:

          -  Exclusion of pregnancy in women with child-bearing potential

          -  Cardiogenic pulmonary oedema

          -  Previous (&lt; 1 month) or ongoing need for corticosteroids &gt;0.1 mg/kg/d
             prednisolon-equivalent or other immune suppressive treatment

          -  Active or previous (&lt; 1 year) treatment for solid or haematologic malignancy

          -  Serum triglycerides &gt; 300 mg/dl at screening

          -  Alterations of coagulation (thrombocytes &lt;100 Giga/l), aPTT &gt; 60 sec, INR ≥ 2.5
             without therapeutic intervention

          -  Autoimmune disease or HIV (according to medical history)

          -  Known or suspected drug abuse

          -  General contraindications to infusion therapy :
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+49-5661-71-0</phone>
    <email>studies@bbraun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinic Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
